StockData
Amgen Inc logo

Amgen Inc (AMGN) operating KPIs

AMGNNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 5, 2026Score 17/3039% above fair value
$466.01+5.28 (+1.15%)

Close on Oct 30, 2026Market cap $251.94BP/E 28.9Yield 2.07%

Amgen neulasta (pegfilgrastim — Febrile Neutropenia) — Worldwide product sales ($M) ($M)

Form 10-Q / 10-K Segment & Revenue Disaggregation Note & Form 8-K Product Sales Detail

QuarterlyAnnual
Latest, Q2 2026
179
Period ended Jun 30, 2026
Change on a year earlier
+118.3%
82 in Q2 2025
History
38 quarters
Since Q1 2017
Sources
33
Documents cited below

Quarterly history

Hover a value to see the sentence it was read from; calculated values show their formula

PeriodEndedNeulasta (pegfilgrastim — Febrile Neutropenia) — Worldwide product sales ($M) ($M)Year on yearSource
Q2 2026Jun 30, 2026179+118.3%Form 8-K (amgn-20260630earningsrelea.htm, filed 2026-08-04) ↗
Q1 2026Mar 31, 2026165+27.9%Form 8-K (amgn-20260331earningsrelea.htm, filed 2026-04-30) ↗
Q4 2025Dec 31, 2025132+34.7%Form 8-K (amgn-20251231earningsrelea.htm, filed 2026-02-03) ↗
Q3 2025Sep 30, 202592-16.4%Form 8-K (amgn-20250930earningsrelea.htm, filed 2025-11-04) ↗
Q2 2025Jun 30, 202582-21.9%Form 8-K (amgn-20250630earningsrelea.htm, filed 2025-08-05) ↗
Q1 2025Mar 31, 2025129+9.3%Form 8-K (amgn-20250331earningsrelea.htm, filed 2025-05-01) ↗
Q4 2024Dec 31, 202498-59.0%Form 8-K (amgn-20241231earningsrelea.htm, filed 2025-02-04) ↗
Q3 2024Sep 30, 2024110-11.3%Form 8-K (amgn-20240930earningsrelea.htm, filed 2024-10-30) ↗
Q2 2024Jun 30, 2024105-55.5%Form 8-K (amgn-20240630earningsrelea.htm, filed 2024-08-06) ↗
Q1 2024Mar 31, 2024118-52.6%Form 8-K (amgn-20240331earningsrelea.htm, filed 2024-05-02) ↗
Q4 2023Dec 31, 2023239+8.1%Form 8-K (amgn-20231231earningsrelea.htm, filed 2024-02-06) ↗
Q3 2023Sep 30, 2023124-49.8%Form 8-K (amgn-2023930earningsrelease.htm, filed 2023-10-31) ↗
Q2 2023Jun 30, 2023236-23.9%Form 8-K (amgn-2023630earningsrelease.htm, filed 2023-08-03) ↗
Q1 2023Mar 31, 2023249-28.4%Form 8-K (amgn-2023331earningsrelease.htm, filed 2023-04-27) ↗
Q4 2022Dec 31, 2022221-37.0%Form 10-K (filed 2023-02-09) ↗
Q3 2022Sep 30, 2022247-40.5%Form 10-Q (filed 2022-11-04) ↗

Breakdown

What makes up neulasta (pegfilgrastim — febrile neutropenia) — worldwide product sales ($m)

Cite this data

StockData. (2026). Amgen Neulasta (pegfilgrastim — Febrile Neutropenia) — Worldwide product sales ($M) ($M), quarterly Q1 2017–Q2 2026 [Data set]. Compiled from Amgen SEC filings and investor materials. https://stockdatahq.com/stocks/amgn/kpis/prod_neulasta_ww

See every metric in the Amgen KPI table. Data updated Oct 28, 2026.